David Lacomis

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Neurosarcoidosis
    David Lacomis
    Departments of Neurology and Pathology Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Curr Neuropharmacol 9:429-36. 2011
  2. doi What's in the literature?
    Ahmed El-Dokla
    Department of Neurology, University of Pittsburgh School of Medicine, UPMC Presbyterian, Pittsburgh, PA, USA
    J Clin Neuromuscul Dis 15:34-42. 2013
  3. doi Electrophysiology of neuromuscular disorders in critical illness
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, 200 Lothrop Street, F878, Pittsburgh, Pennsylvania 15213, USA
    Muscle Nerve 47:452-63. 2013
  4. doi Neuromuscular disorders in critically ill patients: review and update
    David Lacomis
    Department of Neurology and Pathology Neuropathology, University of Pittsburgh School of Medicine, PA, USA
    J Clin Neuromuscul Dis 12:197-218. 2011
  5. doi Electrodiagnostic approach to the patient with suspected myopathy
    David Lacomis
    Division of Neuromuscular Diseases, University of Pittsburgh School of Medicine, UPMC Presbyterian, F875, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Neurol Clin 30:641-60. 2012
  6. ncbi Approach to vasculitic neuropathies
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Clin Neuromuscul Dis 9:265-76. 2007
  7. ncbi Myasthenic crisis
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine Pittsburgh, PA 15213, USA
    Neurocrit Care 3:189-94. 2005
  8. ncbi Neuropathy and Fabry's disease
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Muscle Nerve 31:102-7. 2005
  9. doi The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis
    Ted M Burns
    Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, Virginia 22908, USA
    Muscle Nerve 43:14-8. 2011
  10. pmc The MG Composite: A valid and reliable outcome measure for myasthenia gravis
    Ted M Burns
    University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA 22908, USA
    Neurology 74:1434-40. 2010

Collaborators

Detail Information

Publications41

  1. pmc Neurosarcoidosis
    David Lacomis
    Departments of Neurology and Pathology Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Curr Neuropharmacol 9:429-36. 2011
    ..The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken...
  2. doi What's in the literature?
    Ahmed El-Dokla
    Department of Neurology, University of Pittsburgh School of Medicine, UPMC Presbyterian, Pittsburgh, PA, USA
    J Clin Neuromuscul Dis 15:34-42. 2013
    ..Finally, the spectrum of small fiber neuropathy may be expanding to include a causative role in some patients with fibromyalgia syndrome and in juveniles with diffuse pain and a possible autoimmune predisposition. ..
  3. doi Electrophysiology of neuromuscular disorders in critical illness
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, 200 Lothrop Street, F878, Pittsburgh, Pennsylvania 15213, USA
    Muscle Nerve 47:452-63. 2013
    ..The aim of this study was to review the important role of electrophysiology in this setting...
  4. doi Neuromuscular disorders in critically ill patients: review and update
    David Lacomis
    Department of Neurology and Pathology Neuropathology, University of Pittsburgh School of Medicine, PA, USA
    J Clin Neuromuscul Dis 12:197-218. 2011
    ..Future studies of well-characterized patients with CIP and CIM should refine our understanding of risk factors, outcomes, and pathogenic mechanisms, leading to better interventions...
  5. doi Electrodiagnostic approach to the patient with suspected myopathy
    David Lacomis
    Division of Neuromuscular Diseases, University of Pittsburgh School of Medicine, UPMC Presbyterian, F875, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Neurol Clin 30:641-60. 2012
    ..Electromyography may also be used to detect subclinical myopathy, assess disease activity, and help select a suitable muscle for biopsy...
  6. ncbi Approach to vasculitic neuropathies
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Clin Neuromuscul Dis 9:265-76. 2007
    ..The mainstays of treatment are corticosteroids and cyclophosphamide, but other drugs are used in specific conditions. With early diagnosis and careful monitoring of treatment regimens, the prognosis is usually good...
  7. ncbi Myasthenic crisis
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine Pittsburgh, PA 15213, USA
    Neurocrit Care 3:189-94. 2005
    ..The mortality rate should be 5% or less, with the elderly being most vulnerable...
  8. ncbi Neuropathy and Fabry's disease
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Muscle Nerve 31:102-7. 2005
    ..Histopathologic assessment of nerve and muscle biopsy specimens led to the diagnosis of Fabry's disease, thus allowing the patient to receive enzyme replacement therapy that may slow progression and preserve the transplanted kidney...
  9. doi The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis
    Ted M Burns
    Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, Virginia 22908, USA
    Muscle Nerve 43:14-8. 2011
    ..More objective measures, such as the MG Composite, should also be used to follow disease severity...
  10. pmc The MG Composite: A valid and reliable outcome measure for myasthenia gravis
    Ted M Burns
    University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA 22908, USA
    Neurology 74:1434-40. 2010
    ..To study the concurrent and construct validity and test-retest reliability in the practice setting of an outcome measure for myasthenia gravis (MG)...
  11. doi MG-ADL: still a relevant outcome measure
    Srikanth Muppidi
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Muscle Nerve 44:727-31. 2011
    ..The aim of this analysis was to examine the performance of the Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL) during a multicenter scale validation study...
  12. pmc Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics
    Henrik Ryberg
    Department of Pathology, University of Pittsburgh School of Medicine, BST S 420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA
    Muscle Nerve 42:104-11. 2010
    ..CRP levels were increased in the CSF of ALS patients, and cystatin C level correlated with survival in patients with limb-onset disease. Our biomarker panel predicted ALS with an overall accuracy of 82%...
  13. ncbi Severe sensory neuropathy associated with long-term linezolid use
    Sasa A Zivkovic
    Department of Neurology, University of Pittsburgh School of Medicine, PA, USA
    Neurology 64:926-7. 2005
  14. ncbi The utility of muscle biopsy
    David Lacomis
    University of Pittsburgh Medical Center, UPMC Presbyterian, 200 Lothrop Street, F878, Pittsburgh, PA 15213, USA
    Curr Neurol Neurosci Rep 4:81-6. 2004
    ..Muscle biopsy specimens are used in diagnosing many inherited as well as inflammatory and toxic myopathies. Furthermore, the study of muscle histopathology can also enhance our understanding of disease pathogenesis...
  15. pmc Applying proteomics to the diagnosis and treatment of ALS and related diseases
    Robert Bowser
    Department of Pathology, University of Pittsburgh School of Medicine, BST S 420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA
    Muscle Nerve 40:753-62. 2009
    ..The continued development of protein biomarkers for MNDs requires extensive collaboration between academic clinicians and scientists in conjunction with the biotechnology and pharmaceutical industries...
  16. ncbi Critical illness myopathy
    David Lacomis
    University of Pittsburgh Medical Center Presbyterian, 200 Lothrop Street, F878, Pittsburgh, PA 15213, USA
    Curr Rheumatol Rep 4:403-8. 2002
    ..In some patients, there is also upregulation of proteolytic pathways, involving calpain and ubiquitin, in conjunction with increased apoptosis. Fortunately, the disorder is reversible, but there may be considerable morbidity...
  17. ncbi Electrodiagnostic approach to the patient with suspected myopathy
    David Lacomis
    Departments of Neurology and Pathology Neuropathology, University of Pittsburgh, School of Medicine, 200 Lothrop Street, PUH F 878, Pittsburgh, PA 15213, USA
    Neurol Clin 20:587-603. 2002
    ..Histopathologic or molecular studies, or both may follow. Ultimately, this approach usually allows the clinician to make the correct diagnosis...
  18. pmc Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis
    Meghan E Wilson
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 5:e15133. 2010
    ....
  19. ncbi What's in the Literature?
    Nicholas J Silvestri
    Department of Neurology, University at Buffalo School of Medicine and Biomedical Sciences, SUNY, Buffalo, NY Departments of Neurology and Pathology Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    J Clin Neuromuscul Dis 15:179-90. 2014
    ..Last, we highlight a report of a clinical method of differentiating organic from nonorganic upper extremity weakness. ..
  20. doi What's in the Literature?
    Ahmed El-Dokla
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY and Division of Neuropathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    J Clin Neuromuscul Dis 15:129-42. 2014
    ..Last, the topics in amyotrophic lateral sclerosis that are addressed include regional and distant disease spread, the clinical and prognostic utility of neck flexor weakness, and exercise and focal brain lesions as risk factors. ..
  21. doi Characteristics of late-onset myasthenia gravis
    Sasa A Zivkovic
    Neurology Service, Department of Veterans Affairs, Pittsburgh, PA 15240, USA
    J Neurol 259:2167-71. 2012
    ..However, overall disease severity may not be higher with aging. These observations have implications for design of MG clinical trials and outcomes studies...
  22. pmc SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy
    Leah Winer
    Department of Neurology, Washington University, St Louis, Missouri 63110, USA
    JAMA Neurol 70:201-7. 2013
    ..Therapies designed to decrease the level of SOD1 are currently in a clinical trial for patients with superoxide dismutase (SOD1)-linked familial amyotrophic lateral sclerosis (ALS)...
  23. ncbi Clinical utility of peripheral nerve biopsy
    David Lacomis
    University of Pittsburgh Medical Center, UPMC Presbyterian, 200 Lothrop Street, F878, Pittsburgh, PA 15213, USA
    Curr Neurol Neurosci Rep 5:41-7. 2005
    ..In addition, the study of nerve histopathology can also enhance our understanding of disease pathogenesis...
  24. doi Severe hydroxychloroquine myopathy
    Hoda Abdel-Hamid
    Department of Pediatrics, Division of Child Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Muscle Nerve 38:1206-10. 2008
    ..The ventilatory failure and subsequent medical complications led to death despite discontinuation of hydroxychloroquine, thereby underscoring the potential severity of hydroxychloroquine myopathy and the need for its early recognition...
  25. pmc Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis
    Srikanth Ranganathan
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Neurochem 95:1461-71. 2005
    ..We validated the SELDI-TOF-MS results for transthyretin and cystatin C by immunoblot and immunohistochemistry using commercially available antibodies. These findings identify a panel of CSF protein biomarkers for ALS...
  26. doi What's in the Literature?
    Ahmed El-Dokla
    Department of Neurology, University of Pittsburgh School of Medicine, UPMC Presbyterian, Pittsburgh, PA
    J Clin Neuromuscul Dis 15:77-86. 2013
    ..Advances in clinical and basic science concepts of myotonic dystrophy are also reviewed. ..
  27. doi Paraproteinemic neuropathy
    Sasa A Zivkovic
    VA Pittsburgh Healthcare System, MSSL Neurology, Pittsburgh, PA, USA
    Leuk Lymphoma 50:1422-33. 2009
    ..At this time it is not clear whether mere presence of neuropathy warrants more aggressive treatment of otherwise quiescent hematologic malignances (e.g. smoldering myeloma)...
  28. ncbi Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals
    Munmun Chattopadhyay
    Department of Neurology, University of Pittsburgh, USA
    Eur J Neurosci 17:732-40. 2003
    ....
  29. ncbi Localized scleroderma and regional inflammatory myopathy
    Sasa A Zivkovic
    Neurology Service, Department of Veterans Affairs, Pittsburgh, PA 15240, USA Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA Electronic address
    Neuromuscul Disord 24:425-30. 2014
    ..Muscle biopsy can confirm the diagnosis of myositis, which if identified, will require anti-inflammatory and/or immunosuppressive therapy. ..
  30. doi Peer recommendations on how to improve clinical research, and Conference wrap-up
    David A Chad
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Amyotroph Lateral Scler Frontotemporal Degener 14:67-73. 2013
    ..In this paper, we present the reports from each of the Breakout Sessions; and we provide a wrap-up of the entire conference...
  31. ncbi Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy
    Alan R Berger
    Department of Neurology, University of Florida, USA
    J Peripher Nerv Syst 8:282-4. 2003
  32. pmc Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome
    Tyler B Tarr
    Department of Neuroscience, Center for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    J Neurosci 33:10559-67. 2013
    ..This new Ca(2+) channel agonist has potential as a lead compound in the development of new therapeutic approaches to a variety of disorders that result in neuromuscular weakness...
  33. ncbi Critical illness neuromyopathies
    David Lacomis
    Departments of Neurology and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Adv Neurol 88:325-35. 2002
  34. ncbi Small-fiber neuropathy
    David Lacomis
    Department of Neurology, University of Pittsburgh School of Medicine, UPMC Presbyterian, 200 Lothrop Street, F878, Pittsburgh, Pennsylvania 15213, USA
    Muscle Nerve 26:173-88. 2002
    ..Each has certain advantages and disadvantages, and the tests may be complementary. Unless an underlying disease is identified, treatment is usually directed toward alleviation of neuropathic pain...
  35. ncbi Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy
    Amy H Kao
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Arthritis Rheum 50:209-15. 2004
    ..To determine the long-term outcome and associated clinical, serologic, and pathologic features in a cohort of patients with connective tissue disease (CTD) and the anti-signal recognition particle (anti-SRP) autoantibody...
  36. doi R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS
    Hua Wang
    Department of Neurology, University of Virginia School of Medicine, Charlottesville, Virginia, USA
    Amyotroph Lateral Scler 9:50-8. 2008
    ..High doses of R+PPX were tolerated well and yielded neuroprotective plasma levels. These findings support longer-term testing of higher R+PPX doses as a potential disease-altering therapy for SALS...
  37. doi Neuromuscular pathology case
    Angela Lu
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    J Clin Neuromuscul Dis 9:361-3. 2008
  38. doi Construct and concurrent validation of the MG-QOL15 in the practice setting
    Ted M Burns
    Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA
    Muscle Nerve 41:219-26. 2010
    ..The study findings shed light on what troubles MG patients. The MG-QOL15 has construct validity in the clinical practice setting and represents an efficient and valuable tool for assessing HRQOL for patients with MG...
  39. ncbi Chronic eosinophilic perimyositis with persistent myalgias
    Sasa A Zivkovic
    Department of Neurology, University of Pittsburgh School of Medicine, BST South, Room S515, Pittsburgh, Pennsylvania 15213, USA
    Muscle Nerve 25:461-5. 2002
    ..This case illustrates that the diagnosis of eosinophilic perimyositis requires histopathological evaluation, which should be pursued in patients with eosinophilia and persistent myalgia despite normal electromyography and muscle enzymes...
  40. ncbi Muscle cramps associated with localized scleroderma skin lesions: focal dystonia, neuromyotonia, or nerve entrapment?
    Sasa A Zivkovic
    J Rheumatol 33:2549. 2006